Cost analysis of extended half-life recombinant factor IX products in the treatment of haemophilia B in Italy: an update

Authors

  • Andrea Aiello Intexo Società Benefit S.r.l, Milano - Italy
  • Maria E. Mancuso Center for Thrombosis and Haemorrhagic Diseases, Humanitas Clinical and Research Center – IRCCS, Rozzano, Milan - Italy https://orcid.org/0000-0002-7113-4028
  • Serena Leone Intexo Società Benefit S.r.l, Milano - Italy
  • Letizia Rossi Intexo Società Benefit S.r.l, Milan - Italy
  • Lorenzo Cioni Swedish Orphan Biovitrum, Milan - Italy
  • Cristina Teruzzi Swedish Orphan Biovitrum, Milan - Italy https://orcid.org/0000-0002-3009-6467

DOI:

https://doi.org/10.33393/grhta.2022.2331

Keywords:

Cost Analysis, Haemophilia B, Italy, Prophylaxis, rFIXFc

Abstract

Haemophilia B (HB) is a rare disease which may lead to chronic disabling arthropathy, resulting in a significant clinical, social and economic impact. In recent years, new extended half-life (EHL) factor IX concentrates produced by recombinant technology (rFIX) have been developed. They have shown significantly prolonged half-life as compared to other rFIX products and improved bleeding control when used as prophylaxis. To date, EHL rFIX products reimbursed in Italy are a recombinant coagulation factor IX produced with Fc technology (rFIXFc) and a recombinant fusion protein containing rFIX fused with recombinant albumin (rIX-FP). The results of extension studies with injection intervals with a median of almost every 14 days for the complete individualized interval prophylaxis (IP) group on rFIXFc and 21 days for a selected subgroup of patients on rIX-FP have recently been published.
The aim of this analysis was to estimate the cost of prophylactic treatment with rFIXFc and rIX-FP in adult patients, in the light of new clinical evidence and current average prices in Italy.
The cost of therapy was estimated on the basis of the results of extension studies, the average prices reported in regional drug tenders and assuming an average patient weight of 70 kg.
The analysis estimated a cost per patient/year between €224,407 and €230,355 for rFIXFc and between €242,259 and €368,587 for rIX-FP. The sensitivity analysis confirmed the robustness of the results.
The use of rFIXFc over rIX-FP proves to be the least expensive choice for the treatment of HB in Italy.

References

Aiello A, Mancuso M, Colombo A, Teruzzi C, Berto P. Budget impact analysis of extended half-life recombinant factor IX (rFIXFc) in the treatment of haemophilia B. Glob Reg Health Technol Assess 2020;7(1):40-49. DOI 10.33393/grhta.2020.2113 DOI: https://doi.org/10.33393/grhta.2020.2113

Kodra Y, Cavazza M, Schieppati A, et al. The social burden and quality of life of patients with haemophilia in Italy. Blood Transfus. 2014;12 Suppl 3:s567-s575. https://doi.org/10.2450/2014.0042-14s.

Abbonizio F, Arcieri R, Associazione Italiana Centri Emofilia (AICE) e Giampaolo A. Registro Nazionale Coagulopatie Congenite. Rapporto 2018. Roma: Istituto Superiore di Sanità; 2020. (Rapporti ISTISAN 20/14). https://www.iss.it/rapporti-istisan/-/asset_publisher/Ga8fOpve0fNN/content/rapporto-istisan-20-14-registro-nazionale-coagulopatie-congenite.-rapporto-2018.-francesca-abbonizio-romano-arcieri-associazione-italiana-centri-emofilia-aice-e-adele-giampaolo

Srivastava A, Santagostino E, Dougall A, et al; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia. 3rd edition. Haemophilia. 2020;26(S6)(suppl 6):1-158. https://doi.org/10.1111/hae.14046 PMID:32744769 DOI: https://doi.org/10.1111/hae.14046

Mancuso ME, Lubetsky A, Pan-Petesch B, et al. Long-term safety and efficacy of rIX-FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B. J Thromb Haemost. 2020;18(5):1065-1074. https://doi.org/10.1111/jth.14778 PMID:32078256 DOI: https://doi.org/10.1111/jth.14778

Pasi KJ, Fischer K, Ragni M, et al. Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: results from the B-YOND extension study. Haemophilia. 2020;26(6):e262-e271. https://doi.org/10.1111/hae.14036 PMID:32497409 DOI: https://doi.org/10.1111/hae.14036

Shapiro AD, Pasi KJ, Ozelo MC, et al. Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B. Res Pract Thromb Haemost. 2018;3(1):109-113. https://doi.org/10.1002/rth2.12163 PMID:30656283 DOI: https://doi.org/10.1002/rth2.12163

Published

2022-01-19

How to Cite

1.
Aiello A, Mancuso ME, Leone S, Rossi L, Cioni L, Teruzzi C. Cost analysis of extended half-life recombinant factor IX products in the treatment of haemophilia B in Italy: an update. Grhta [Internet]. 2022 Jan. 19 [cited 2022 Sep. 26];9(1):9-13. Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/2331

Issue

Section

Short Communication